Open-label phase 1/2 study of vestronidase alfa for mucopolysaccharidosis VII

Abstract

Vestronidase alfa is an enzyme replacement therapy for mucopolysaccharidosis VII (MPS VII). In this open-label, phase 1/2 study, three subjects with MPS VII received intravenous vestronidase alfa administered every other week (QOW) for 14 weeks (2 mg/kg), followed by 24-week forced-dose titration (1, 4, and 2 mg/kg QOW; 8 weeks each), 36-week continuation (2 mg/kg), and long-term extension (4 mg/kg). Vestronidase alfa was well tolerated and led to dose-responsive, sustained reductions in urinary glycosaminoglycan excretion.

Keywords

• Vestronidase alfa
• Recombinant human β-glucuronidase
• Enzyme replacement therapy
• Mucopolysaccharidosis VII
• MPS VII
• Phase 1/2